Biblio Discovery — Demo Discovery Service

54 results for "Adam L. Boxer"

Showing 1–20 · 0.27 seconds · RSS

  1. Journal Article

    24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome

    Ingemar Björkhem; Kalicharan Patra; Adam L. Boxer et al.

    Frontiers in Neurology, Vol. 9 · 2018 · English · DOAJ Scopus

    24S-hydroxycholesterol (24OHC) and Tau are produced in neuronal cells and neurodegeneration leads to increased flux of both of them into cerebrospinal fluid (CSF). In the present study, CSF levels of 24OHC and 27S-hydroxycholesterol (27OHC) along with those of Tau, P-Thr181-Tau and Aβ42 were…

  2. Journal Article

    Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues

    Niyatee Samudra; Courtney Lane-Donovan; Lawren VandeVrede et al.

    The Journal of Clinical Investigation, Vol. 133 No. 12 · 2023 · English · DOAJ Scopus

    Tauopathies are disorders associated with tau protein dysfunction and insoluble tau accumulation in the brain at autopsy. Multiple lines of evidence from human disease, as well as nonclinical translational models, suggest that tau has a central pathologic role in these disorders, historically…

  3. Journal Article

    Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial

    Marian L. Dale; Barbara H. Brumbach; Adam L. Boxer et al.

    Frontiers in Neurology, Vol. 11 · 2020 · English · DOAJ Scopus

    Introduction: Amantadine anecdotally improves gait in progressive supranuclear palsy (PSP) but definitive data is lacking. We investigated associations between amantadine usage, gait, cognition, and activities of daily living in 310 subjects with PSP using data from the davunetide trial.Method: We…

  4. Journal Article Full text

    C9orf72 repeat expansion initially presenting as late-onset bipolar disorder with psychosis

    Leslie S., Gaynor; Golnaz, Yadollahikhales; Elena, Tsoy et al.

    Neurologist · 2024 · English · PubMed Central

    INTRODUCTION: C9orf72 expansion is the most common genetic abnormality in behavioral variant frontotemporal dementia (bvFTD) and amyotrophic lateral sclerosis (ALS). While psychiatric prodromes are common in C9orf72 expansion carriers, there are only scattered reported cases of primary psychiatric…

  5. Journal Article Full text

    The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

    Oskar Hansson; Rebecca M. Edelmayer; Adam L. Boxer et al.

    Alzheimer s & Dementia · 2022 · English · OpenAlex Scopus

    Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We…

  6. Journal Article

    Longitudinal white matter change in frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease

    Fanny M. Elahi; Gabe Marx; Yann Cobigo et al.

    NeuroImage: Clinical, Vol. 16 · 2017 · English · DOAJ Scopus

    Background: Degradation of white matter microstructure has been demonstrated in frontotemporal lobar degeneration (FTLD) and Alzheimer's disease (AD). In preparation for clinical trials, ongoing studies are investigating the utility of longitudinal brain imaging for quantification of disease…

  7. Journal Article

    Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab

    Lawren VandeVrede; Daniel M Gibbs; Mary Koestler et al.

    Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol. 12 No. 1 · 2020 · English · DOAJ Scopus

    Abstract Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele. Methods We describe the clinical course and management of a 66‐year‐old white male (APOE ε4/ε4)…

  8. Journal Article

    A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance

    Tien Dam; Lili Yang; Colin Gillis et al.

    Nature Communications, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder characterized by physical, cognitive, and behavioral impairments. The PSP Rating Scale (PSPRS) is a widely used and validated, clinical scale to monitor disease progression. Here we show the modification of PSPRS to…

  9. Journal Article Full text

    An Epigenetic Signature in Peripheral Blood Associated with the Haplotype on 17q21.31, a Risk Factor for Neurodegenerative Tauopathy

    Yun Li; Jason A. Chen; Renee L. Sears et al.

    PLoS Genetics, Vol. 10 No. 3 · 2014 · English · PLOS Scopus

    Little is known about how changes in DNA methylation mediate risk for human diseases including dementia. Analysis of genome-wide methylation patterns in patients with two forms of tau-related dementia – progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) – revealed significant…

    Also available at: DOAJ

  10. Journal Article

    Reward processing deficits arise early in familial frontotemporal dementia

    Noah G. Cryns; Emily G. Hardy; Ashlin R. K. Roy et al.

    Frontiers in Neuroscience, Vol. 18 · 2024 · English · DOAJ Scopus

    Reward processing involves evaluation of stimuli to inform what an individual works to pursue or avoid. Patients with behavioral variant frontotemporal dementia (bvFTD) often display reward processing changes, including insensitivity to aversive stimuli. It is unknown how early in the disease…

  11. Journal Article

    Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy

    Jesse A. Brown; Alice Y. Hua; Andrew Trujillo et al.

    NeuroImage: Clinical, Vol. 16 · 2017 · English · DOAJ Scopus

    Progressive supranuclear palsy syndrome (PSP-S) results from neurodegeneration within a network of brainstem, subcortical, frontal and parietal cortical brain regions. It is unclear how network dysfunction progresses and relates to longitudinal atrophy and clinical decline. In this study, we…

  12. Journal Article Full text

    Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study

    Yu Zhang; Rudolph Walter; Peter Ng et al.

    PLOS ONE, Vol. 11 No. 6 · 2016 · English · PLOS Scopus

    Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are both 4 microtubule binding repeat tauopathy related disorders. Clinical trials need new biomarkers to assess the effectiveness of tau-directed therapies. This study investigated the regional distribution of longitudinal…

    Also available at: DOAJ

  13. Journal Article

    Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy

    Xu Chen; Yaqiao Li; Chao Wang et al.

    Molecular Neurodegeneration, Vol. 15 No. 1 · 2020 · English · DOAJ Scopus

    Abstract Background The trans-neuronal propagation of tau has been implicated in the progression of tau-mediated neurodegeneration. There is critical knowledge gap in understanding how tau is released and transmitted, and how that is dysregulated in diseases. Previously, we reported that lysine…

  14. Journal Article

    Single-cell RNA-seq reveals alterations in peripheral CX3CR1 and nonclassical monocytes in familial tauopathy

    Daniel W. Sirkis; Caroline Warly Solsberg; Taylor P. Johnson et al.

    Genome Medicine, Vol. 15 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Background Emerging evidence from mouse models is beginning to elucidate the brain’s immune response to tau pathology, but little is known about the nature of this response in humans. In addition, it remains unclear to what extent tau pathology and the local inflammatory response within…

  15. Journal Article

    Treatment of Disturbed Sleep in Progressive Supranuclear Palsy: a randomized, remote, double-blinded, 6-week cross-over design study protocol comparing zolpidem, suvorexant, and placebo

    Esther Li; Felicia Song; Quentin Coppola et al.

    Trials, Vol. 27 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Prior research identified profound sleep disruption in progressive supranuclear palsy (PSP). The hypothalamus and brainstem, areas that help regulate sleep/wake patterns, are among the earliest affected brain regions in PSP disease progression. Comparing polysomnography and…

  16. Journal Article

    Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort

    Sang Won Seo; Nagehan Ayakta; Lea T. Grinberg et al.

    NeuroImage: Clinical, Vol. 13 No. C · 2017 · English · DOAJ Scopus

    Imaging-pathological correlation studies show that in vivo amyloid-β (Aβ) positron emission tomography (PET) strongly predicts the presence of significant Aβ pathology at autopsy. We sought to determine whether regional PiB-PET uptake would improve sensitivity for amyloid detection in comparison…

  17. Journal Article Full text

    Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

    Keith A. Vossel; Kamalini G. Ranasinghe; Alexander J. Beagle et al.

    JAMA Neurology · 2021 · English · OpenAlex Scopus

    Importance: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). Objective: To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD. Design, Setting, and Participants: The Levetiracetam for…

  18. Journal Article Full text

    Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease

    Salvatore E. Spina; Renaud La Joie; Cathrine Petersen et al.

    Brain · 2021 · English · OpenAlex Scopus

    Co-pathologies play an important role in the expression of the Alzheimer's disease clinical phenotype and may influence treatment efficacy. Early-onset Alzheimer's disease, defined as manifesting before age 65, is viewed as a relatively pure form of Alzheimer's disease with a more homogeneous…